Glitazones and the cardiovascular system

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 2, 2008, Pages 188-192

  Devchand, Pallavi R ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Peroxisome proliferator activated receptor; Pioglitazone; PPAR coactivator 1 ; Retinoid X receptor; Rosiglitazone

Indexed keywords

FABP4 INHIBITOR; GLITAZONE DERIVATIVE; LIPID BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PROTEIN FABP4; PROTEIN INHIBITOR; RETINOID X RECEPTOR; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; RETINOID;

ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CIRCADIAN RHYTHM; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; GENE REPRESSION; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION REGULATION; X RAY CRYSTALLOGRAPHY; ANIMAL; ANIMAL MODEL; CHEMISTRY; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, ANIMAL; PPAR GAMMA; RETINOIDS; THIAZOLIDINEDIONES;

EID: 42449151300     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f79b20     Document Type: Review

References (46)

1. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115:518-533.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471. The metaanalysis that instigated questions regarding cardiovascular safety of Avandia in patients.
3. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007; 357:28-38. Interim analyses of the ongoing RECORD trial, showing no real concerns that would warrant stopping patients from using rosiglitazone.
4. •] above, indicating Actos does not present with similar cardiovascular safety concerns as Avandia.
5. Harris PK, Kletzien RF. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol Pharmacol 1994; 45:439-445.
6. Tontonoz P, Graves RA, Budavari AI, et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 1994; 22:5628-5634.
7. Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68:879-887.
8. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-12956.
9. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83:803-812.
10. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptorgamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24:78-90.
11. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 2007; 115:2540-2548.
12. Arany Z, Novikov M, Chin S, et al. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1 alpha. Proc Natl Acad Sci U S A 2006; 103:10086-10091. This paper describes the role of PGC1α in mouse biogenic response to cardiac stress.
13. Rohas LM, St-Pierre J, Uldry M, et al. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci U S A 2007; 104:7933-7938.
14. Duncan JG, Fong JL, Medeiros DM, et al. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor alpha/PGC-1alpha gene regulatory pathway. Circulation 2007; 115:909-917.
15. Ding G, Fu M, Qin Q, et al. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res 2007; 76:269-279.
16. Einstein M, Akiyama T, Castriota G, et al. The differential interactions of PPARgamma ligands with tyrosine 473 is a physical basis for their unique biological activities. Mol Pharmacol 2008; 73:62-74.
17. Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 2007; 25:57-70. This paper endorses the notion that ligand-induced transrepression via the NCoR-HDAC3 complex is a basic mechanism used by nuclear hormone receptors.
18. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437:759-763.
19. Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ. Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. Mol Cell Endocrinol 2006; 256 (1-2):23-33.
20. Metzger D, Chambon P. Contribution of targeted conditional somatic mutagenesis to deciphering retinoid X receptor functions and to generating mouse models of human diseases. Handb Exp Pharmacol 2007; (178):511-524.
21. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68:397-406.
22. Ziouzenkova O, Orasanu G, Sukhova G, et al. Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol 2007; 21:77-88. This is conceptually a powerful study that approaches endogenous regulation of nuclear receptors through enzymatic production of ligands.
23. Schupp M, Curtin JC, Kim RJ, et al. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity. Mol Pharmacol 2007; 71:1251-1257.
24. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005; 18 (4 Pt 1):549-556.
25. Anan F, Masaki T, Fukunaga N, et al. Pioglitazone shift circadian rhythm of blood pressure from nondipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest 2007; 37:709-714.
26. McNamara P, Seo SP, Rudic RD, et al. Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell 2001; 105:877-889.
27. Yang X, Downes M, Yu RT, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006; 126:801-810.
28. Thorp E, Kuriakose G, Shah YM, et al. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation 2007; 116: 2182-2190. This is an important study from the vantage point of safety of glitazones.
29. Werner C, Kamani CH, Gensch C, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007; 56:2609-2615.
30. Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7:699-705.
31. Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447:959-965.
32. Cabré A, Lázaro I, Girona J, et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007; 195:e150-e158.
33. Tan NS, Shaw NS, Vinckenbosch N, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 2002; 22:5114-5127.
34. Schug TT, Berry DC, Shaw NS, et al. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007; 129:723-733.
35. Michalik L, Wahli W. Guiding ligands to nuclear receptors. Cell 2007; 129:649-651.
36. Kershaw EE, Schupp M, Guan HP, et al. PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo. Am J Physiol Endocrinol Metab 2007; 293:E1736-E1745.
37. Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354:2552-2563.
38. Jin W, Wang X, Millar JS, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 2007; 6:129-136.
39. Ahmed W, Orasanu G, Nehra V, et al. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 2006; 98:490-498.
40. Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Contribution to the standardization of the chromatographic conditions for the lipophilicity assessment of neutral and basic drugs. Anal Chim Acta 2006; 573-574:311-318.
41. Colca JR, McDonald WG, Waldon DJM, et al. Identification of a novel mitochondrial protein ('mitoNEET') cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004; 286:E252-E260.
42. Wiley SE, Murphy AN, Ross SAM, et al. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U S A 2007; 104:5318-5323.
43. Wiley SE, Paddock ML, Abresch ECM, et al. The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster. J Biol Chem 2007; 282:23745-23749.
44. Paddock ML, Wiley SE, Axelrod HLM, et al. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A 2007; 104:14342-14347. This paper describes the X-ray crystal structure of mitoNEET, demonstrating specific interactions with pioglitazone.
45. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007; 99 (4A):27B-40B.
46. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508-519.